Paliroden clinical trials
Also written SR57667B.
How each study uses paliroden is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the paliroden studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SR57667B
- 4
Studies by the year they started
4 studies that test it; most in 2004 (2); 2 more planned to start later
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses paliroden is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy SituationsNot yet recruitingPhase 1/2Cilcare SASNCT07472907Written as CIL001 (Paliroden)
- A Study Testing Safety and Efficacy of Transtympanic Paliroden for the Treatment of Cochlear Synaptopathy in Participants With Chronic, Constant TinnitusNot yet recruitingPhase 1/2Cilcare SASNCT07826507Written as paliroden (CIL001)
- Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's DiseaseCompletedPhase 2SanofiNCT00228150Written as SR57667B
- Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's DiseaseCompletedPhase 2SanofiNCT00220272Written as SR57667B
- Long-Term Safety Extension With SR57667B in Patients With Alzheimer's DiseaseCompletedPhase 2SanofiNCT00285077Written as SR57667B
- Study of the Effect of SR57667B in Patients With Alzheimer's DiseaseCompletedPhase 2SanofiNCT00285025Written as SR57667B
Codes
What other systems call paliroden · ClinicalTrials.gg INT014292
- UNII (FDA) 17VJ76L90TPALIRODENConfirmed FDA, Wikidata
- Wikidata Q27251945palirodenConfirmed FDA, Wikidata
- NCI Thesaurus C82298PalirodenOne source FDA
- DrugBank DB05454One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 17VJ76L90T | PALIRODEN | Confirmed FDA, Wikidata |
| Wikidata | Q27251945 | paliroden | Confirmed FDA, Wikidata |
| NCI Thesaurus | C82298 | Paliroden | One source FDA |
| DrugBank | DB05454 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.